"A preshow": Drug makers respond to Trump"s emergency plans in opioid crisis
U. S. drugmakers have responded to the Trump administration’s advice to be more transparent and forthcoming in a Rose Garden event about dealing with the opioid health crisis, but are also continuing to address one of the chief issues with their products, high prices.
Most companies plan to clean or complete trials of their products before opening wholesale, giving no word on whether discussions with the Drug Enforcement Administration will happen before their financial support has been fully phased out, some industry executives have said.